XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration and Licensing Agreements - Narrative (Details)
$ in Millions, ¥ in Billions
 1 Months Ended 3 Months Ended 9 Months Ended 59 Months Ended
Nov. 30, 2019
USD ($)
segment
item
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Nov. 30, 2017
USD ($)
Jun. 30, 2015
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2022
CAD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2022
JPY (¥)
Apr. 11, 2022
USD ($)
payment_tranche
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Revenue           $ 4,986,000 $ 1,173,000 $ 7,980,000   $ 9,068,000      
Cost of revenue           732,000 0 955,000   1,000,000      
Licensing revenue                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Revenue           9,000 2,000 23,000   5,007,000      
Product supply revenue                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Revenue           92,000 285,000 1,058,000   411,000      
2019 KKC Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Revenue           0 900,000 0   3,700,000      
2019 KKC Agreement | KKC                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Upfront license fees $ 10,000,000                        
First installment of upfront license fees $ 5,000,000                        
Term of payment of license fee, first installment 30 days                        
Second installment of upfront license fees $ 5,000,000                        
Term of agreement 2 years                        
Number of amendments | segment 3                        
2017 KKC Agreement | Licensing revenue                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Revenue           0 0 0   5,000,000 $ 10,000,000    
2017 KKC Agreement | Product supply revenue                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Revenue           83,000 300,000 1,000,000   400,000      
2017 KKC Agreement | KKC                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Upfront license fees       $ 30,000,000                  
Potential development milestones       $ 55,000,000                  
Potential commercialization milestones           58,700,000   58,700,000     58,700,000 ¥ 8.5  
Fee receivable for reduction in royalty rate                         $ 40,000,000
Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche                         2
Fosun Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Revenue             0     0      
Fosun Agreement | Product supply revenue                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Revenue           9,000   9,000          
Fosun Agreement | Fosun Pharma                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Potential development milestones           3,000,000   3,000,000     3,000,000    
Upfront payment received     $ 12,000,000                    
Potential development and commercialization milestones               $ 113,000,000          
Threshold percentage of net sales for tiered royalties               20.00% 20.00%        
Knight Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Revenue             2,000     7,000      
Knight Agreement | Licensing revenue                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Revenue           9,000   $ 23,000          
Knight Agreement | Knight                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Potential development milestones           700,000   700,000     700,000    
Upfront payment received   $ 2,300,000                      
Potential development and commercialization milestones               16,100,000 $ 22.2        
AZ Termination Agreement | AstraZeneca                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Percentage of royalty revenue         10.00%                
Percentage of non-royalty revenue         20.00%                
Maximum potential payment per agreement         $ 75,000,000                
Aggregate cost of revenue recognized           12,400,000   12,400,000     12,400,000    
Aggregate amount paid           11,600,000   11,600,000     $ 11,600,000    
Cost of revenue           $ 500,000 $ 0 $ 800,000   $ 1,000,000      
Minimum | 2019 KKC Agreement | KKC                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Number of separate collaborative agreements | item 1